Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verastem Inc
(NQ:
VSTM
)
2.820
+0.030 (+1.08%)
Streaming Delayed Price
Updated: 11:05 AM EDT, Jul 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verastem Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
March 14, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
March 11, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
March 05, 2024
From
Verastem Oncology
Via
Business Wire
Where Verastem Stands With Analysts
November 15, 2023
Via
Benzinga
Analyst Ratings for Verastem
September 27, 2023
Via
Benzinga
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
March 05, 2024
From
Verastem Oncology
Via
Business Wire
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 12, 2024
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and...
Via
Benzinga
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
February 07, 2024
Discover AI's top stock selections, meticulously analyzed for 2024, promising more than just returns but a revolution in your portfolio.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
January 29, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
January 18, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 11, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
December 18, 2023
From
Verastem Oncology
Via
Business Wire
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
December 13, 2023
Although there’s safety in numbers, many times, you need to consider uncommon stocks to buy for growth for robust upside.
Via
InvestorPlace
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
December 13, 2023
From
Verastem Oncology
Via
Business Wire
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
December 03, 2023
Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing.
Via
InvestorPlace
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
November 13, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 08, 2023
From
Verastem Oncology
Via
Business Wire
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
November 07, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
November 06, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
October 26, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
October 14, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
September 28, 2023
From
Verastem Oncology
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
September 27, 2023
Via
Benzinga
Verastem Oncology to Participate in Upcoming Investor Conferences
September 05, 2023
From
Verastem Oncology
Via
Business Wire
3 Penny Stocks That Can Triple Your Money in the Next 12 Months
September 04, 2023
Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing.
Via
InvestorPlace
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
September 02, 2023
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet...
Via
Talk Markets
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
August 28, 2023
From
Verastem Oncology
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.